Ikarian Capital, LLC C4 Therapeutics, Inc. Transaction History

Ikarian Capital, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$35.91 - $50.5 $632,015 - $888,800	-17,600 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$30.39 - $42.18 $2.85 Million - $3.96 Million	-93,900 Reduced 84.22%	17,600 $666,000
Q1 2021 May 17, 2021	SELL	$31.96 - $46.5 $1.28 Million - $1.86 Million	-40,000 Reduced 26.4%	111,500 $4.12 Million
Q4 2020 Feb 12, 2021	BUY	$22.8 - $37.05 $3.45 Million - $5.61 Million	151,500 New	151,500 $5.02 Million

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $230M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.